Zoetis (ZTS)
Health Care · Animal Health · NYSE
Zoetis is a leader in the global animal health industry, providing a broad range of innovative medicines, vaccines, and diagnostics for pets and livestock.
Price as of 2026-10-29 close.
- Market cap
- $32.6B
- P/E
- 12.9
- Next earnings
- Nov 5, 2026 (confirmed)
| 3M | 6M | 1Y | |
|---|---|---|---|
| ZTS | +1.1% | -30.8% | -45.3% |
| S&P 500 (SPY) | +5.5% | +8.1% | +11.9% |
Informational only — not financial advice.
Long-term picture
| Business quality | 7/10 | above average | vs covered US companies |
|---|---|---|---|
| Price vs fundamentals | 6/10 | middle of the pack | vs covered US companies, some measures within its sector |
| Long-run trend | 3/10 | below average | vs covered US companies |
| Cash returned to shareholders | 8/10 | above average | vs covered US companies |
An above-average business at a price in the middle of the field. The long-run trend is down. This reads published data; it is not a recommendation.
Is the price reasonable?
| Today | Own history: low – median – high | Fiscal years | Range | |
|---|---|---|---|---|
| P/E | 12.9 | 20.9 – 32.6 – 57.1 | 5 | |
| P/S | 3.4 | 5.9 – 8.5 – 15.0 | 5 | |
| P/FCF | 14.1 | 24.5 – 52.0 – 67.0 | 5 |
Bar: its own fiscal-year low to high, the tick is the median, the dot is today.
- P/E is 13 today. Over its last 5 fiscal years it ranged 21 to 57, median 33.
- P/S is 3.4 today. Over its last 5 fiscal years it ranged 5.9 to 15, median 8.5.
- P/FCF is 14 today. Over its last 5 fiscal years it ranged 24 to 67, median 52.
At today's price the market is assuming free cash flow grows about 4% a year for ten years. Over the last three years free cash flow grew 20% a year.
This is a simple model with fixed assumptions (9% discount rate, 2.5% growth after year ten). It shows what the price assumes; it is not a price target.
As of 2026-10-29. How this is computed.
What would change this picture
- Return on equity is 80.2%, which is strong for covered US companies (percentile 97.3).
- P/E is 12.9 against the Health Care median of 28.6.
- The price is 16.3% below its 200-day average.
- Next results 2026-11-05 (confirmed); analysts expect EPS between $1.44 and $1.61.
- Risks the company itself lists in its latest filing.
Scores come from the published Top 10 method, as of 2026-10-29; technical indicators as of 2026-10-29; analyst estimates as of 2026-10-22. See what this is.
What Zoetis does
Zoetis is a global animal health company dedicated to the discovery, development, manufacture, and commercialization of medicines, vaccines, and diagnostic products for pets and livestock. The company serves veterinarians, livestock producers, and pet owners with a diverse portfolio spanning vaccines, parasiticides, anti-infectives, and pain management therapeutics.
Themes: pet care, livestock health, veterinary medicine, animal diagnostics, animal vaccines
Fundamentals
- Price$78.80
- Market cap$32.6B as of 2026-07-31 (share count; price 2026-10-29)
- 1-year return-45.3% 2025-10-29 close $143.94 → 2026-10-29 close $78.80
- P/E12.9
- Net margin28.2%
- ROE80.2%
- ROIC29.4% NOPAT / (debt + equity - cash), average capital — 10-K FY2025 (year ended 2025-12-31) — EBIT = pre-tax income + interest expense (the 10-K tags no operating income)
- Debt / equity2.87 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+2.3%
- Revenue CAGR (3y)+5.4%
- Beta0.53
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Sources and dates — Price: as of 2026-10-29 close · P/E: as of 2026-10-29 · Net margin, ROE, Revenue growth (YoY): FY2025, SEC XBRL · Revenue CAGR (3y): SEC XBRL · Beta: as of 2026-09-02
Dividend: forward yield 2.69% (forward yield, latest regular dividend annualized); 13-year non-decreasing per-share dividend streak (SEC XBRL).
How ZTS compares in its sector
- price-to-earnings ratio12.9 · bottom 25% median 28.0
- net profit margin28.2% · top 10% median -8.0%
- return on equity80.2% · top 10% median -23.0%
- 3-year revenue CAGR5.4% · middle range median 10.5%
- indicated dividend yield2.7% · top 25% median 1.1%
- free cash flow (absolute dollars, latest fiscal year)$2.3B · top 10% median $-25.0M
Dot: where it sits among covered Health Care peers (0 = lowest value, 100 = highest); tick: the sector median.
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better").
Top 10 scores & list membership
ZTS is not currently in any published Top 10 list. Its scores are below.
Top 10 score
53.3 #529 of 1,308 scored · #69 of 155 in Health Care
Profitability 97th (return on equity 80.2%) and capital return 78th (consecutive years of dividend increases 13 years, net share count bought back over the year 2.4); weakest is trend (22nd, a "death cross" — its 50-day average is below its 200-day).
Scores as of 29 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, ZTS's dividend was covered by reported results (earnings payout 33%, free-cash-flow payout 39%). This describes past coverage, not a forecast.
- Earnings payout33% dividends / net income
- Free-cash-flow payout39% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items.
Quarterly results
Reported annual figures from the company's 10-K filings (SEC XBRL); actuals only, no estimates.
| Quarter | Revenue | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY26 2026-06-30 | $2.5B | $691M | $1.65 | $655M† | $117M† |
| Q1 FY26 2026-03-31 | $2.3B | $601M | $1.42 | $401M | $110M |
| Q4 FY25 2025-12-31 | $2.4B† | $603M† | $1.37† | $893M† | $161M† |
| Q3 FY25 2025-09-30 | $2.4B | $721M | $1.63 | $891M† | $136M† |
| Q2 FY25 2025-06-30 | $2.5B | $726M | $1.63 | $605M† | $146M† |
| Q1 FY25 2025-03-31 | $2.2B | $602M | $1.34 | $515M | $178M |
| Q4 FY24 2024-12-31 | $2.3B† | $581M† | $1.29† | $905M† | $216M† |
| Q3 FY24 2024-09-30 | $2.4B | $682M | $1.50 | $951M† | $167M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$1.5B
- Short-term investments$200M
- Total debt$9.0B borrowings only; leases excluded
- Net debt$7.4B total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed.
How Zoetis looks technically
Zoetis (ZTS) is trading 16.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 458 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 6 trading days ago. It is 46.7% below its highest point of the past year.
Trend
7
| Distance from the 200-day | What it meansit is trading 16.3% below its 200-day average, the long-term trend line — a long-term downtrend | -16.3% |
|---|---|---|
| 50-day moving average | What it meansits average price over the last 50 trading days — a short-term trend line — is $74.95 | $74.95 |
| 200-day moving average | What it meansits average price over the last 200 trading days — the long-term trend line — is $94.19 | $94.19 |
| Swing structure | What it meansits recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | What it meansits last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | What it meansits 50-day average crossed below its 200-day average about 458 trading days ago — a "death cross", a bearish long-term signal | 458 sessions |
| Trend strength (14-day ADX) | What it meansa strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with buyers in control | 31.7 |
Momentum
3
| 14-day RSI | What it meansmomentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 57.8 |
|---|---|---|
| Position in its 14-day range | What it meansit is trading in the upper half of its 14-day range ($74.17 to $82.29) — its "stochastic" reading is 57 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 57.0 |
| Since the MACD crossed zero | What it meansMACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 18 sessions |
Range
12
| 52-week high | What it meansits highest closing price over the past year (about 252 trading days) was $147.93 | $147.93 |
|---|---|---|
| From the 52-week high | What it meansit is 46.7% below its 52-week high (its highest price of the past year) | -46.7% |
| Above the 52-week low | What it meansit is 14.6% above its 52-week low (its lowest price of the past year) | +14.6% |
| Below the 52-week high | What it meansit is 46.7% below its highest point of the past year | 46.7% |
| Since a 20-day breakout | What it meansit made a new 20-day high about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | What it meansit made a new 55-day high about 6 trading days ago | 6 sessions |
| All-time high | What it meansits highest closing price on record is $249.27 (set on 2021-12-30) | $249.27 |
| Given back of the 52-week move | What it meansover the past year its closes ranged ($69.10 to $147.53), and it has recovered only a small part of its fall from last year’s high — 12% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $117.57 to $120.08. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 12.4% |
| From the all-time high | What it meansit is 68.4% below its all-time high | -68.4% |
| Nearest price level | What it meansit is trading 0.8% above a support level at $78.20 — a price it turned at four times since 2026-07-07, most recently on 2026-09-03. Since 2024-10-29 it has 3 such levels below the current price and 15 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.8% |
| All-time low | What it meansits lowest closing price on record is $26.00 (set on 2013-01-31) | $26.00 |
| Above the all-time low | What it meansit is 203.1% above its all-time low | +203.1% |
Volatility
5
| Band width vs its own 6 months | What it meansday-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | What it meansin a typical session it travels about $1.85 between its high and its low — about 2.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.85 |
| Bollinger bands (20-day, ±2σ) | What it meansmost of its recent trading has stayed between about $69.31 and $83.99 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $69.31 – $76.65 – $83.99 |
| Typical daily range (% of price) | What it meansits price moves about 2.4% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.4% |
| Stretch from the 200-day average | What it meansit is trading 8.3 daily ranges below its 200-day average price (16.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | What it meanstrading volume is about normal versus its 30-day average | 0.71× |
|---|
Analyst
2
| Change in the average price target | What it meansanalysts have cut their average price target by 2.0% since the prior reading | -2.0% |
|---|---|---|
| Change in the consensus rating | What it meansthe analyst consensus rating has softened toward "sell" since the prior reading | 0.12 toward sell |
Candlestick patterns
1
| Since a doji | What it means3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|
Price gaps
2
| Gap at the open | What it meansit opened on 2026-10-29 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Gap filled | What it meansa 6.0% gap up opened on 2026-08-06 has been "filled" 59 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 59 sessions ago |
Price streaks
1
| Closing streak | What it meansit closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | What it meansover the past 1 month this stock beat the market by 11.4 percentage points (the stock gained 12.1% while the market gained 0.7%) | +11.4% |
|---|---|---|
| vs market, 3 months | What it meansover the past 3 months this stock lagged the market by 4.4 percentage points (the stock gained 1.1% while the market gained 5.5%) | -4.3% |
| vs market, 6 months | What it meansover the past 6 months this stock lagged the market by 38.9 percentage points (the stock lost 30.8% while the market gained 8.1%) | -38.9% |
| vs market, 12 months | What it meansover the past 12 months this stock lagged the market by 57.2 percentage points (the stock lost 45.3% while the market gained 11.9%) | -57.2% |
Signal agreement
2
| Bullish technical signals | What it means3 of the 9 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, a strong uptrend, with buyers in control, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | What it means3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | What it meanstrading 4.8% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-23 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.1% of the share price. | +4.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | What it meansthe price is 13% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $90.62 — a volume-weighted average of daily closes over 206 sessions, not a true tick-by-tick VWAP. | -13.0% |
|---|---|---|
| Vs the average paid since it last reported | What it meansthe price is 5% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $74.76 — a volume-weighted average of daily closes over 60 sessions, not a true tick-by-tick VWAP. | +5.4% |
Price levels it has turned at before
ZTS last closed at $78.80 on 2026-10-29. Since 2024-10-29 it has turned at 3 prices below its last close and 15 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $78.20 | Support | 0.8% below the last close | turned there four times · 2026-07-07 to 2026-09-03 |
| $82.34 | Resistance | 4.5% above the last close | turned there three times · 2026-05-22 to 2026-10-22 |
| $73.51 | Support | 6.7% below the last close | turned there three times · 2026-05-15 to 2026-07-23 |
| $71.23 | Support | 9.6% below the last close | turned there twice · 2026-06-30 to 2026-08-17 |
| $115.42 | Resistance | 46.5% above the last close | turned there twice · 2025-11-19 to 2025-12-10 |
| $118.11 | Resistance | 49.9% above the last close | turned there twice · 2025-11-07 to 2026-02-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-29.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading above the 50-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · Analyst price target recently CUT · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-29. Describes past price behavior only.
Analyst consensus
- Consensus ratingBuy (2.47 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$93.00 range $74.00 – $155.00; median $85.00
Analyst estimates, as of 2026-10-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm.
Analyst EPS estimate for ZTS
- Consensus EPS estimate$1.50 next reporting period, as of 2026-10-22
- Estimate change, 30 days-$0.00318 (-0.2%) from $1.51, on 2026-09-17, 35-day window
- Readings revised upward30% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. It is not a forecast.
Key risks (from latest filing)
- Regulatory risks associated with the approval, manufacturing, and marketing of animal health products.
- Significant competition within the global animal health industry.
- Reliance on patents and proprietary technology to protect products.
What changed in the latest 10-Q
AI-assisted comparison of ZTS's 10-Q filed 2026-05-07 against the prior one filed 2025-11-04.
- Management's Discussion & Analysis (MD&A) · Added: Added reference to 'nearly 75 years' legacy (newer filing, 2026-05-07)
- Management's Discussion & Analysis (MD&A) · Added: Added statement about 'operational and other changes made in connection with the change in accounting principle to eliminate the one-month financial reporting lag in 2026 for our subsidiaries operating outside the U.S.' in Quarterly Variability section (newer filing, 2026-05-07)
- Management's Discussion & Analysis (MD&A) · Added: Added 'and supply availability' to factors affecting quarterly variability (newer filing, 2026-05-07)
Show all
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'nearly 75 years' legacy (newer filing, 2026-05-07)
- Added statement about 'operational and other changes made in connection with the change in accounting principle to eliminate the one-month financial reporting lag in 2026 for our subsidiaries operating outside the U.S.' in Quarterly Variability section (newer filing, 2026-05-07)
- Added 'and supply availability' to factors affecting quarterly variability (newer filing, 2026-05-07)
- Added reference to 'customer expectations related to' timing of price increases (newer filing, 2026-05-07)
- Removed:
- Removed statement 'For over 70 years, we have been innovating ways' (older filing, 2025-11-04)
- Removed statement 'Through our efforts to establish an early and direct presence in many emerging markets, such as Brazil, Chile, China and Mexico, we believe we are one of the largest animal health medicines and vaccines business as measured by revenue across emerging markets as a whole' (older filing, 2025-11-04)
- Removed nine-month period performance table for the nine months ended September 30, 2025 vs 2024 (older filing, 2025-11-04)
- Removed reference to '2024 Annual Report on Form 10-K' in Operating Environment section (older filing, 2025-11-04)
- Removed 'supply chain disruption' as standalone factor; consolidated into other language (older filing, 2025-11-04)
- Removed reference to 'Part II., Item 1A, Risk Factors in this Quarterly Report on Form 10-Q' (older filing, 2025-11-04)
- Reworded:
- Changed 'For over 70 years, we have been innovating ways to predict, prevent, detect, and treat animal illness, and continue to stand by those' to 'With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those' (newer filing, 2026-05-07)
- Changed 'offer a diversified product portfolio' to 'offer diverse products' (newer filing, 2026-05-07)
- Changed performance comparison period from 'Three Months Ended September 30, 2025 vs 2024' to 'Three Months Ended March 31, 2026 vs 2025' (newer filing, 2026-05-07)
- Changed foreign currency revenue percentage from 'approximately 41%' (nine months ended September 30, 2025) to 'approximately 47%' (three months ended March 31, 2026) (newer filing, 2026-05-07)
- Changed U.S. dollar revenue percentage from 'approximately 59%' (nine months ended September 30, 2025) to 'approximately 53%' (three months ended March 31, 2026) (newer filing, 2026-05-07)
- Changed foreign exchange impact from 'unfavorably impacted by approximately 1' to 'favorably impacted by approximately 4%' (newer filing, 2026-05-07)
- Changed reference from '2025 Annual Report on Form 10-K' to '2025 Annual Report on Form 10-K' and changed Risk Factors reference from 'Part II., Item 1A' to 'Part I., Item 1A' (newer filing, 2026-05-07)
- Changed 'factors which could' to 'factors that could' (newer filing, 2026-05-07)
- Notes:
- The newer filing covers a three-month period (Q1 2026) while the older filing covered nine-month period (YTD 2025), making some comparisons period-specific rather than narrative changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only and makes no materiality, legal, or investment judgement.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-25. The 6 days since 2026-10-25 have not been checked yet.
- Last 180 days · read to 2026-10-253 buys ($886367) · 0 sells — 3 buying insiders
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of ZTS within a 30-day window between 2026-05-11 and 2026-05-13. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-05-13. Based on Form 4 filings read through 2026-10-25; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ZTS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 26 matched disclosures for ZTS from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 of the 10 institutional managers we track reported holding ZTS (13F, quarter ended 2026-06-30; a quarter-end position filed within 45 days, not every institution that holds it).
- Tracked 13F managers holding it 6 of 10
- Reported shares held 71.4M
- Reported value $5.1B
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade.
Ask about ZTS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ZTS had 18,424,459 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
ZTS had 4.46% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.09 days to cover at the same settlement.
- Reported short interest (shares) 18.4M
- Short interest (% of shares outstanding) 4.46%
- Prior settlement (shares) 17.4M
- Reported change 5.95%
- Days to cover (reported) 4.09
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float.
Competitors & peers
- Merck Animal Health (MRK)
- Boehringer Ingelheim Animal Health
- Elanco Animal Health (ELAN)
- IDEXX Laboratories (IDXX)
- Dechra Pharmaceuticals
- Ceva Santé Animale
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ZTS vs…
Zoetis is found in…
ZTS ranks in…
ZTS shows up in…
Frequently asked questions
What does Zoetis (ZTS) do?
Zoetis is a global animal health company dedicated to the discovery, development, manufacture, and commercialization of medicines, vaccines, and diagnostic products for pets and livestock. The company serves veterinarians, livestock producers, and pet owners with a diverse portfolio spanning vaccines, parasiticides, anti-infectives, and pain management therapeutics.
What sector is Zoetis (ZTS) in?
Zoetis (ZTS) is classified in the Health Care sector. Its industry is Animal Health. It trades on NYSE.
Does ZTS pay a dividend?
Yes — Zoetis (ZTS) pays a dividend, with a forward yield of about 2.69% (forward yield, latest regular dividend annualized) and 13-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-09-02).
Who are Zoetis's (ZTS) competitors?
Notable peers of Zoetis (ZTS) include Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health, IDEXX Laboratories and Dechra Pharmaceuticals.
Has there been recent U.S. House stock trading in ZTS?
Yes — we hold 26 matched STOCK Act disclosures for ZTS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Zoetis (ZTS) overbought or oversold right now?
Zoetis (ZTS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-10-29). RSI describes recent price momentum, not a forecast.
Where does stocks-llm's data on ZTS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-29.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.